Table 2.
Clinical characteristics and pulmonary function post-TB treatment completion in advanced HIV/TB co-infected patients.
| Clinical variables | (n = 14) |
|---|---|
| Female, n (%) | 7 (50%) |
| Pre-ART HIV viral load, log10 copies/ml (IQR) | 5.2 (4.7–6.0) |
| Pre-ART CD4 T-cell count, median cells/μl (IQR) | 36 (24–79) |
| Age at PFT, mean (range in years) | 40 (27–61) |
| BMI at PFT, median kg/m2 (IQR); | 21.5 (19.4–23) |
| History of smoking, n (%) | 2 (14) |
| ATT initiation-PFT median years (IQR) | 1.9 (1.6–2.1) |
| ART initiation-PFT median years (IQR) | 1.8 (1.5–2.1) |
| Pulmonary function test (PFT) | |
| FEV1a, median % (IQR) | 77.5 (66–83) |
| FVCa, median % (IQR) | 83 (77–91) |
| FEV1/FVC ratioa, median % (IQR) | 97.5 (76–105) |
| Abnormal PFT, n (%) | 9 (64) |
| Obstructive, n (%) | 5 (56) |
| Restrictive, n (%) | 3 (33) |
| Mixed, n (%) | 1 (11) |
Shown are characteristics at baseline and at cross-section for patients who underwent pulmonary function testing (PFT) post-TB treatment completion. IQR = interquartile range; BMI = body mass index; ATT = anti-TB therapy; FEV1 = forced expiratory volume in 1 s; FVC = forced vital capacity.
a
Percent of predicted normal.